16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis

NCT02294227 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

341

Enrollment

INDUSTRY

Sponsor class

Conditions

Arthritis, Psoriatic

Interventions

BIOLOGICAL: Secukinumab
OTHER: Placebo

Sponsor

Novartis Pharmaceuticals